It provides an alternative platform for the development of an oncogenic K-RAS signaling hub-centered and key PDAC tumor vulnerability-based intervention strategy for developing a logical “curative” therapeutic intervention in pancreatic cancer (Figure 2). The gene discussed is KRAS; the disease is pancreatic neoplasm.